Related Experiment Videos
Treatment of hyperkalaemia using intravenous and nebulised salbutamol
R J McClure1, V K Prasad, J T Brocklebank
1Academic Unit of Paediatrics and Child Health, St James's University Hospital, Leeds.
Insights
Nebulized salbutamol effectively lowers high potassium levels in children with chronic renal failure. This method is recommended as a first-line emergency treatment for hyperkalemia, showing better long-term results than intravenous administration.
Area of Science:
- Pediatric Nephrology
- Clinical Pharmacology
- Emergency Medicine
Background:
- End-stage chronic renal failure (CRF) in children often leads to life-threatening hyperkalemia.
- Effective and rapid reduction of plasma potassium is crucial in managing pediatric hyperkalemia.
- Salbutamol is a known agent for potassium reduction, but optimal administration route in pediatric CRF requires clarification.
Purpose of the Study:
- To compare the efficacy of intravenous (IV) versus nebulized salbutamol in reducing plasma potassium levels in children with end-stage CRF.
- To evaluate the safety and side effect profile of both administration methods.
- To determine the preferred route for emergency hyperkalemia treatment in this pediatric population.
Main Methods:
- A study involving 11 children (aged 5-18 years) with end-stage CRF.
- Children received two doses of IV salbutamol (4 mcg/kg each, 2 hours apart) on one date.
- On a separate date, they received nebulized salbutamol (2.5 mg or 5 mg based on weight).
Main Results:
- Both IV and nebulized salbutamol significantly reduced plasma potassium within 30 minutes.
- Nebulized administration showed a trend towards greater potassium reduction at later time points.
- A significant difference favoring nebulization was observed at 300 minutes post-first dose; no major side effects were reported.
Conclusions:
- Nebulized salbutamol is a safe and effective emergency treatment for hyperkalemia in pediatric end-stage CRF.
- Nebulization appears to provide a more sustained reduction in plasma potassium compared to IV administration.
- Nebulized salbutamol should be considered the first-choice emergency treatment for hyperkalemia in this patient group.
Abstract:
In 11 children (aged 5-18 years) with end stage chronic renal failure, the effect on plasma potassium of two doses of salbutamol (separated by two hours) given intravenously (4 micrograms/kg) and on a separate date, of salbutamol administered by nebuliser (2.5 mg if the child weighed below 25 kg, 5 mg if above) was observed. Within 30 minutes of the first dose, the mean plasma potassium concentration fell significantly by 0.87 and 0.61 mmol/l after intravenous and nebulised administration respectively. Sixty minutes after the second dose the plasma potassium was significantly reduced by a further 0.28 and 0.53 mmol/l respectively. There was a significant difference between the two methods of administration at 300 minutes after the first dose favouring nebulisation. No major side effects were observed. Nebulised salbutamol should be the first choice emergency treatment of hyperkalaemia.